Target (CBDY) Total Non-Current Liabilities (2019 - 2026)
Target (CBDY) reported Total Non-Current Liabilities of $795392.0 for Q1 2026, down 15.93% year-over-year from $946124.0 in Q1 2025, and down 7.31% quarter-over-quarter from $858088.0 in Q4 2025.
Target (CBDY) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Target (CBDY) has 8 years of Total Non-Current Liabilities data on file, last reported at $795392.0 in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $795392.0, down 15.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $795392.0 (down 15.93% YoY), and the FY2025 annual result was $858088.0, down 12.86% from the prior year.
- Total Non-Current Liabilities retreated to $795392.0 in Q1 2026 per CBDY's latest filing, from $858088.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $10.8 million in Q1 2022 and troughed at $795392.0 in Q1 2026.
- A 5-year average of $4.0 million and a median of $1.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities slumped 85.3% in 2024, then soared 228.28% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $7.2 million in 2022, then sank by 82.99% to $1.2 million in 2023, then slipped by 19.57% to $984733.0 in 2024, then dropped by 12.86% to $858088.0 in 2025, then declined by 7.31% to $795392.0 in 2026.
- Business Quant data shows CBDY's Total Non-Current Liabilities at $795392.0 in Q1 2026, $858088.0 in Q4 2025, and $890579.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Target | - | - | 191,787.00 | 795,392.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 795,392.00 |
| Dec 31, 2025 | 858,088.00 |
| Sep 30, 2025 | 890,579.00 |
| Jun 30, 2025 | 3.65 Mn |
| Mar 31, 2025 | 946,124.00 |
| Dec 31, 2024 | 984,733.00 |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.16 Mn |
| Dec 31, 2023 | 1.22 Mn |
| Sep 30, 2023 | 6.77 Mn |
| Jun 30, 2023 | 7.56 Mn |
| Mar 31, 2023 | 7.29 Mn |
| Dec 31, 2022 | 7.20 Mn |
| Sep 30, 2022 | 7.01 Mn |
| Jun 30, 2022 | 9.46 Mn |
| Mar 31, 2022 | 10.83 Mn |
| Dec 31, 2021 | 11.17 Mn |
| Sep 30, 2021 | 11.43 Mn |
| Jun 30, 2021 | 13.46 Mn |